SILVER SPRING, Md., July 09, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, effective July 10, 2015, American Stock Transfer & Trust Company (“AST”) will replace Signature Stock Transfer as its stock transfer and dividend disbursing agent.
The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, commented on PharmaCyte Biotech’s new stock transfer agent, “We are extremely pleased to announce that we have appointed AST to be our new stock transfer agent. We are confident that our partnership with this fine organization will provide our shareholders with superior customer service and support. In addition, it will enable us to have access to the industry’s leading management resources and will ensure us the highest quality of operational process that we believe will yield tangible financial benefits to PharmaCyte Biotech and its shareholders.”
AST and its affiliates are leading providers of registry services and technology to financial market participants around the globe. With over 40 years of experience, AST is known for providing a superior customer service experience, which is supported by ongoing investments to technology, people and service offerings. AST has premier in-house call centers, innovative software and processing systems that set the industry standard.
AST provides comprehensive stock transfer and employee plan services to over 2,800 public companies and maintains approximately 6,000 issues. AST’s clients are located throughout the United States and in over 22 foreign countries, ranging in size from initial public offerings to Fortune 100 companies. Founded in 1971 and headquartered in New York, AST provides clients around the globe with customized solutions to fit their specific needs along with access to the best systems, services, processes and products available today.
On and after July 10, 2015, all inquiries and correspondence related to stockholder records, transfer of shares, lost certificates, dividend checks or change of address requests should be directed to AST. If you have questions, please call AST at (800) 937-5449 or email AST at firstname.lastname@example.org. AST can also be contacted via mail at:
PharmaCyte Biotech Inc.
c/o American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
On July 10, 2015, welcome letters with detailed information about AST will be mailed directly to all PharmaCyte Biotech registered shareholders with instructions on how to access their account through AST.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known chemotherapy prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.
In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: 917.595.2856 Email: Info@PharmaCyte.com
Source:PharmaCyte Biotech, Inc.